Fatigue Treatment Using Provigil

All Multiple Sclerosis Patients Clinical Trial

Official title:

Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00220506
• Other study ID #: SHEBA-05-3769-MD-CTIL
• Status: Recruiting
• Phase: N/A
• First received: September 14, 2005
• Last updated: February 16, 2006
• Start date: September 2005
• Est. completion date: December 2006

Study information

• Verified date: February 2006
• Source: Sheba Medical Center
• Contact: Mark Dolev, MD
• Phone: 972-3-5303899
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Interventional

Clinical Trial Summary

To determine whether therapy with Modafinal(Provigil) is safe and effective in fatigue in MS Patients

Description:

Multiple sclerosis and fatigue Fatigue is one of the most common symptoms of multiple sclerosis (MS), occurring in 30%-80% of patients and for many of them fatigue is the most disabling symptom (1).

Definition of fatigue according to the MS Council for Clinical Practice Guidelines is as follows: “A subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities”.

As fatigue is a subjective and non-specific symptom, and can easily be confused with either weakness or depressed mood, both common in MS, the following characteristics have been defined to better diagnose MS-associated fatigue:

• MS-related fatigue generally occurs on a daily basis.

• It tends to worsen as the day progresses.

• It tends to be aggravated by heat and humidity.

• It is not directly correlated with either depression or the degree of physical impairment.

• It may occur first thing in the morning even if the patient has had a restful full night's sleep.

The current medications used for the treatment of MS-associated fatigue such as amantadine hydrochloride and pemoline are useful to some, but not all patients. In a multicenter trial (2) it was found that 100 mg amantadine twice daily significantly improves fatigue. Pemoline in a placebo-controlled trial (3) failed to show significant effect on fatigue in MS patients and was poorly tolerated as side effects occurred in 25% of patients. A third trial (4) compared pemoline to amantadine and placebo, and showed only a positive trend for pemoline, while amantadine had a benefit over placebo in some fatigue measures. There was also a marked placebo effect in this trial, with approximately half of patients reporting improvement in fatigue no matter what treatment (pemoline, amantadine or placebo) they were taking.

In the current study proposal we intend to evaluate the effect of Provigil on MS-associated fatigue.

The possibility for add-on drug that will affect fatigue in MS is of importance, as fatigue has a significant impact on activities of daily living, interfering with work, family life and social activities.

1.2. The fatigue scale named “Fatigue Impact Scale” The awareness of the impact of fatigue on patient’s quality of life (QOL) and the need to evaluate the effect of the different therapies on this parameter resulted in the development and validation of different questionnaires for the measurement of fatigue, i.e., the Fatigue Impact Scale (FIS), which has been shown to measure both, fatigue and treatment effect on fatigue (6-9).

The FIS is a reliable and validated 40-items questionnaire that is capable of selecting a treatment effect. It is a made up of 3 sub-scales: physical, cognitive and social. Each question is scored from 0-4, allowing a total score of 160. High scores indicate high impairment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• The patients should be diagnosed with clinically definite MS (Posner criteria).

• EDSS at screening: 0 to 5.5, inclusive.

• Positive Fatigue impact scale 40 points or more.

• Age 18-55 years.

• Co-operating patient, capable of complying with all of trial procedures (i.e. FIS, QOL, etc…).

• Patient who signed written informed consent.

• Women of childbearing potential must use effective birth control method during study.

Exclusion Criteria:

• Life threatening and/or unstable clinical condition which in the opinion of the investigator might compromise trial completion

• A relapse during the last 30 days prior to the study.

• Systemic steroid therapy within 30 days

• Known hypersensitivity or intolerance, to Provigil or related substances or to any component of the formulation.

• Sleep apnea

• Narcolepsy

• Participation in experimental drug trials during the last 30 days prior to the trial.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• All Multiple Sclerosis Patients
• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Sclerosis

Intervention

Drug:
• Provigil

Locations

Country	Name	City	State
Israel	Multiple Sclerosis Center	Tel Hashomer

Sponsors (1)

Lead Sponsor	Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine fatigue impact scale
Secondary	to determine cognition measurements